IRIS Accounts Production v24.3.2.46 08680558 Board of Directors 30.9.23 29.9.24 29.9.24 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh086805582023-09-29086805582024-09-29086805582023-09-302024-09-29086805582022-09-29086805582022-09-302023-09-29086805582023-09-2908680558ns15:EnglandWales2023-09-302024-09-2908680558ns14:PoundSterling2023-09-302024-09-2908680558ns10:Director12023-09-302024-09-2908680558ns10:PrivateLimitedCompanyLtd2023-09-302024-09-2908680558ns10:SmallEntities2023-09-302024-09-2908680558ns10:AuditExempt-NoAccountantsReport2023-09-302024-09-2908680558ns10:SmallCompaniesRegimeForDirectorsReport2023-09-302024-09-2908680558ns10:SmallCompaniesRegimeForAccounts2023-09-302024-09-2908680558ns10:FullAccounts2023-09-302024-09-2908680558ns5:CurrentFinancialInstruments2024-09-2908680558ns5:CurrentFinancialInstruments2023-09-2908680558ns5:Non-currentFinancialInstruments2024-09-2908680558ns5:Non-currentFinancialInstruments2023-09-2908680558ns5:ShareCapital2024-09-2908680558ns5:ShareCapital2023-09-2908680558ns5:RetainedEarningsAccumulatedLosses2024-09-2908680558ns5:RetainedEarningsAccumulatedLosses2023-09-2908680558ns10:RegisteredOffice2023-09-302024-09-2908680558ns5:FurnitureFittings2023-09-302024-09-2908680558ns5:FurnitureFittings2023-09-2908680558ns5:FurnitureFittings2024-09-2908680558ns5:FurnitureFittings2023-09-2908680558ns5:WithinOneYearns5:CurrentFinancialInstruments2024-09-2908680558ns5:WithinOneYearns5:CurrentFinancialInstruments2023-09-29
REGISTERED NUMBER: 08680558 (England and Wales)















UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 29 SEPTEMBER 2024

FOR

CAMBRIDGE MEDTECH SOLUTIONS LIMITED

CAMBRIDGE MEDTECH SOLUTIONS LIMITED (REGISTERED NUMBER: 08680558)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 29 SEPTEMBER 2024










Page

Statement of Financial Position 1 to 2

Notes to the Financial Statements 3 to 6


CAMBRIDGE MEDTECH SOLUTIONS LIMITED (REGISTERED NUMBER: 08680558)

STATEMENT OF FINANCIAL POSITION
29 SEPTEMBER 2024

29.9.24 29.9.23
Notes £    £   
FIXED ASSETS
Tangible assets 4 3,303 2,496

CURRENT ASSETS
Debtors 5 651 436
Cash at bank 101,457 179,860
102,108 180,296
CREDITORS
Amounts falling due within one year 6 (56,827 ) (108,843 )
NET CURRENT ASSETS 45,281 71,453
TOTAL ASSETS LESS CURRENT
LIABILITIES

48,584

73,949

CREDITORS
Amounts falling due after more than one
year

7

-

(30,000

)

PROVISIONS FOR LIABILITIES (627 ) (495 )
NET ASSETS 47,957 43,454

CAPITAL AND RESERVES
Called up share capital 100 100
Retained earnings 47,857 43,354
47,957 43,454

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 29 September 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 29 September 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

CAMBRIDGE MEDTECH SOLUTIONS LIMITED (REGISTERED NUMBER: 08680558)

STATEMENT OF FINANCIAL POSITION - continued
29 SEPTEMBER 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 28 March 2025 and were signed on its behalf by:





S B W Kay - Director


CAMBRIDGE MEDTECH SOLUTIONS LIMITED (REGISTERED NUMBER: 08680558)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 29 SEPTEMBER 2024


1. STATUTORY INFORMATION

Cambridge Medtech Solutions Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address are as below:

Registered number: 08680558

Registered office: c/o DPC
Stone House
55 Stone Road Business Park
Stoke-On-Trent
Staffordshire
ST4 6SR

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The financial statements are prepared in sterling, which is the functional currency of the entity.

Significant judgements and estimates
The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

(i) Estimated useful lives and residual values of fixed assets

Depreciation of tangible fixed assets has been based on estimated useful lives and residual values deemed appropriate by the directors. Estimated useful lives and residual values are reviewed annually and revised as appropriate. Revisions take into account estimated useful lives used by other companies operating in the sector and actual asset lives and residual values, as evidenced by disposals during the current and prior accounting periods.

Revenue recognition
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Revenue from the rendering of services is recognised by reference to the stage of completion at the balance sheet date; the amount of revenue can be measured reliably, it is probable that the associated economic benefits will flow to the entity, and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off the cost less estimated residual value of each asset over its estimated useful life.
Fixtures and fittings - 15% reducing balance

Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

CAMBRIDGE MEDTECH SOLUTIONS LIMITED (REGISTERED NUMBER: 08680558)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 29 SEPTEMBER 2024


2. ACCOUNTING POLICIES - continued

Financial instruments
A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Debt instruments are subsequently measured at amortised cost.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Research and development
Expenditure on research and development is written off in the year in which it is incurred.


Impairment of fixed assets
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

For the purposes of impairment testing, when it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs.

For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.

CAMBRIDGE MEDTECH SOLUTIONS LIMITED (REGISTERED NUMBER: 08680558)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 29 SEPTEMBER 2024


2. ACCOUNTING POLICIES - continued

Provisions
Provisions are recognised when the entity has an obligation at the reporting date as a result of a past event, it is probable that the entity will be required to transfer economic benefits in settlement and the amount of the obligation can be estimated reliably. Provisions are recognised as a liability in the statement of financial position and the amount of the provision as an expense.

Provisions are initially measured at the best estimate of the amount required to settle the obligation at the reporting date and subsequently reviewed at each reporting date and adjusted to reflect the current best estimate of the amount that would be required to settle the obligation. Any adjustments to the amounts previously recognised are recognised in profit or loss unless the provision was originally recognised as part of the cost of an asset.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2023 - 2 ) .

4. TANGIBLE FIXED ASSETS
Fixtures
and
fittings
£   
COST
At 30 September 2023 5,717
Additions 1,332
At 29 September 2024 7,049
DEPRECIATION
At 30 September 2023 3,221
Charge for year 525
At 29 September 2024 3,746
NET BOOK VALUE
At 29 September 2024 3,303
At 29 September 2023 2,496

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
29.9.24 29.9.23
£    £   
Other debtors 651 436

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
29.9.24 29.9.23
£    £   
Trade creditors 1,016 -
Taxation and social security 666 25,348
Other creditors 55,145 83,495
56,827 108,843

CAMBRIDGE MEDTECH SOLUTIONS LIMITED (REGISTERED NUMBER: 08680558)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 29 SEPTEMBER 2024


7. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
29.9.24 29.9.23
£    £   
Other creditors - 30,000

8. RELATED PARTY DISCLOSURES

During the year the company owed 18,748 to the directors (2023: £111,285)

All other transactions undertaken with the directors are deemed to be conducted under normal market conditions and/or are not material.